Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

December 15, 2015

Primary Completion Date

October 16, 2019

Study Completion Date

October 24, 2019

Conditions
Pancreatic TumoursMidgut Neuroendocrine Tumours
Interventions
DRUG

Lanreotide autogel 120 mg

Trial Locations (32)

1066

AVL/NKI Medisch Oncologie, Amsterdam

1070

Erasme Hospital, Brussels

1105

Academic Medical Center, Amsterdam

1200

Cliniques Unversitaires Saint Luc, Brussels

2100

Rigshospitalet, Copenhagen

2650

Antwerp University Hospital, Edegem

3015

Erasmus MC, Rotterdam

13273

Institut Paoli Calmette, Marseille

13353

Charité - CVK, Berlin

16132

IRCCS Azienda Ospedaliera Universitaria, San Martino

20133

Fondacione IRCCS Istituto Nazionale Dei Tumori, Milan

28034

Hospital Universitario Ramón Y Cajal, Madrid

28041

Hospital Universitario 12 De Octubre, Madrid

33011

Hospital Universitario Central de Asturias, Oviedo

50134

Azienda Ospedaliera - Universitaria Careggi, Florence

69120

Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg

69437

Hôpital Edouard Herriot, Lyon

80131

"Università degli Studi Federico II di Napoli", Napoli

91054

Universitätsklinikum Erlangen, Erlangen

92118

Hôpital Beaujon, Clichy

94805

Institut Gustave Roussy, Villejuif

B-3000

UZ Leuven, Leuven

Unknown

Aarhus University Hospital, Aarhus

D4

St Vincent's University Hospital, Dublin

00189

Azienda Ospedaliera sant'Andrea, Roma

40-952

Samodzielny Publiczny Szpital Kliniczny nr 5, Katowice

60-355

Katedra i Klinika Endokrynologii, Poznan

02-348

"Centrum Diagnostyczno-Lecznicze GAMMED", Warsaw

08034

Hospital Universitario Vall D'hebron, Barcelona

B15 2TH

Queen Elizabeth Medical Center, Birmingham

NW3 2QG

Royal Free Hospital, London

M20 4BX

The Christie Hospital NHS Foundation Trust, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY